
    
      This is a 2-period crossover study and consists of two cohorts. Cohort 1 consists of
      participant's with greater than or equal to (>=) 40.0 kilogram (kg) to lesser than or equal
      to (<=) 75.0 kg of weight and Cohort 2 consists of participant's with greater than (>) 75.0
      kg to <= 120.0 kg of weight. Participants in each cohort will be randomized to 1 of 2
      treatment periods (Period I and Period II) with sequence AB and BA. Randomization will be
      stratified by injection site (i.e., thigh, abdomen, and arm) within each cohort.
    
  